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ABSTRACT
Genetic screens, where the effects of modifying gene
function on cell behaviour are assessed in a systematic
fashion, have for some time provided useful information to
those interested in disease pathogenesis and treatment.
Genetic screens exploiting the phenomenon of RNA
interference (RNAi) are now becoming commonplace.
This article explains the different RNAi screen formats and
describes some of the applications of RNAi screening that
may be pertinent to the research pathologist.
RNA INTERFERENCE (RNAI): WHAT, HOW AND
WHY?
Put simply, experimental RNAi allows the research
scientist to assess the function of a gene or protein
by silencing its expression using synthetic RNAs or
plasmids (an effect often referred to as ‘‘knock-
down’’). This technique exploits a physiological
mechanism that represses gene expression by
causing the degradation of protein-coding messen-
ger RNA (mRNA) transcripts. In mammalian cells,
physiological RNAi is primarily mediated by non-
protein-coding RNA transcripts, known as
microRNAs (miRNAs) (fig 1). miRNAs are pro-
duced in much the same way as normal mRNAs,
but instead of being translated into proteins,
miRNAs are processed into shorter RNA species
containing a hairpin structure, known as short-
hairpin RNAs (shRNAs). These are in turn
processed into short double-stranded pieces of
RNA known as short-interfering RNAs (siRNAs).
Within a multiprotein complex known as RISC
(RNA-induced silencing complex), one strand of a
siRNA duplex binds a protein-coding mRNA
transcript that bears a complementary nucleotide
sequence. This interaction allows a nuclease in
RISC to cleave and destroy the protein-coding
mRNA, thus silencing the expression of the gene in
a relatively sequence-specific manner (fig 1).
In 1998, Mello and Fire demonstrated that
potent gene silencing could be experimentally
induced by injecting double-stranded (ds)RNA into
the nematode Caenorhabditis elegans. In this con-
text, dsRNA is processed into siRNA by an
enzyme, Dicer.
1 In mammalian cells, however,
the introduction of long dsRNAs induces an
interferon response that confounds experimental
results, primarily by inducing an interferon
response that causes a global shutdown of protein
synthesis.
2 However, synthetic siRNAs, or plas-
mids expressing shRNAs or miRNAs which are
processed into siRNAs, can be introduced into
mammalian cells and mediate gene silencing with-
out significant adverse effects.
2
The experimental use of synthetic siRNAs and
shRNA plasmids has profoundly changed the way
in which the loss of function of particular genes or
proteins is studied. Previously, techniques that
were either more time consuming, such as gene
targeting (making ‘‘knockout’’ cell lines or ani-
mals), or capricious, such as antisense RNA, were
used. Alternatively specific inhibitors of a particu-
lar protein could be used, but these are limited in
scope. Now RNAi reagents can be purchased and
trivially used to silence almost any gene in the
genome.
As described above, the types of RNAi reagents
fall into two main categories, siRNAs and shRNA
expression constructs. Table 1 shows the advan-
tages of each reagent format. siRNAs consist of
small double-stranded pieces of RNAs (generally
over 19 bp), one strand of which matches a
complementary sequence in the gene to be knocked
down. These siRNAs can be either synthetically
synthesised or generated by enzyme digestion of
mRNA, a technique known as esiRNA.
3 The main
advantage of siRNAs is ease of use; given their
small size, siRNAs are readily transfected into most
cell types, and they can be purchased in ‘‘ready-to-
transfect’’ format from many commercial suppli-
ers. One limitation of siRNAs, however, is that
gene silencing is only achieved over a short period
of time; siRNAs are most likely degraded by the
host cell and are also not replicated along with
the host cell’s DNA. Therefore, as cells prolifer-
ate, the proportion of cells carrying siRNA is
gradually reduced. To some extent, this short
period of silencing (a number of days) has been
addressed by chemical modification of siRNA (see
www.dharmacon.com), but if long-term silencing
is required, shRNA expression constructs are
more often the solution. These constructs express
miRNAs or shRNAs that are processed by the
target cell’s own RNA-processing machinery into
siRNA, which in turn mediate gene silencing.
These constructs come in a variety of formats
and can be purchased either as simple plasmids or
as viral constructs that are easier to deliver to a
wider range of cell lines. shRNA vector-based
reagents can provide long-term, stable gene
silencing, as the vectors used are able to integrate
into genomic DNA and are thus copied along
with cellular DNA. Although the inherent
instability of some of the initial viral systems
used to express shRNA limited their utility, this
problem has now been addressed in the most
recent versions that are available from commer-
cial suppliers. One of the more recent advances in
shRNA construct design has been the use of
vectors that express miRNAs instead of shRNAs.
It is proposed that, as this process more closely
mirrors the mechanism by which endogenous
mammalian miRNAs mediate gene silencing, it
leads to an improvement in silencing efficiency.
45
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design also raise the possibility of in vivo RNAi screens in
whole animals, as opposed to in vitro screens in cultured cells.
Already, individual genes can be targeted in mice using RNAi,
6
and, in fact, candidate tumour suppressor genes have been
validated using this approach.
7
siRNAs and shRNA expression constructs are now available
as libraries that contain reagents targeting any number of genes.
Depending on the application, RNAi reagents targeting a single
gene, a particular gene subset, for example protein kinases, or
indeed the entire genome may be purchased. The commercial
availability of such reagents now means that a number of genes
can be screened simultaneously, and relatively straightfor-
wardly, for their involvement in a chosen biological phenotype.
The format of how such a screen is performed is largely
determined by the choice of RNAi reagent. Both shRNAs and
siRNAs are well suited to ‘‘one gene per well’’ screens (fig 2)
where cells are transfected or infected in multi-well plates, each
well containing RNAi reagents that silence one gene. Normally
96-well or 384-well plates are used for such screens, meaning
that the entire genome can be screened using under two
hundred 384-well plates or just over six hundred 96-well plates.
Obviously such screens are better performed using some form of
liquid handling automation, although smaller screens where a
gene subset such as the protein kinases are targeted can be
performed manually using only ten 96-well plates. The simplest
screens of this type use some form of plate reader to measure
the effect of RNAi reagents; measuring cell viability by the use
of an ATP colorimetric assay is common. However, the recent
trend is to measure multiple phenotypes within the same
screen, sometimes using high-throughput microscopy, an
approach termed ‘‘high-content’’ analysis. For example, Bakal
et al
8 recently screened a small gene subset by RNAi using high-
throughput microscopy to measure changes in cell morphology.
Although the computational requirements to analyse such high-
content screens properly are high, these approaches offer the
potential to dissect complex biological networks and pathways.
The scale of whole-genome screens that involve the use of
hundreds of multi-well plates can often be daunting. Given this,
an alternative approach is to use shRNA-expression constructs
in ‘‘pooled’’ screens (fig 2). Here, pools of shRNA-expressing
vectors are used to infect or transfect cells, which are then
selected for the phenotype of interest such as resistance to a
small-molecule inhibitor. The target gene in surviving cells is
identified by PCR amplification and sequencing of the unique
short hairpin sequence of the shRNA vector that encodes the
gene-specific shRNA. Relatively new sequencing platforms,
such as ABI SOLiD (Roche 454) and Illumina’s Genome
Analyzer II are ideal for this purpose as they are able to
simultaneously sequence millions of short pieces of DNA, such
as PCR products containing short hairpin sequences of shRNAs.
An alternative approach for screening deconvolution is to use
oligonucleotide microarrays to identify hits from pooled shRNA
screens. These technologies can be used to identify shRNA
targets that are either selected for (positive selection) or selected
against (negative selection). For example, Brummelkamp and
colleagues
9 used a library targeting ,8000 genes in a positive bar
code screen to identify mediators of sensitivity to the anticancer
drug Nutlin-3, an inhibitor of Mdm2 that activates the p53
pathway, allowing a more complete understanding of the
mechanism of tumour selectivity for this drug.
9 Such pooled
approaches are not limited to drug-sensitisation screens. For
example, Green and colleagues screened ,62 400 shRNAs
targeting ,28 000 mouse genes to analyse the mechanisms
that control the cell surface expression of the pro-apoptotic Fas
receptor.
10 The ,62 400 shRNAs were divided into 10 pools,
which were packaged into retrovirus particles and used to stably
transduce Fas receptor-negative, K-ras NIH 3T3 cells. Cells in
which Fas receptor expression had been induced by RNAi were
selected from the total cell population using immunomagnetic
beads bearing an anti-Fas antibody. This Fas receptor-positive
population was expanded, and the shRNAs that caused
expression of the receptor were identified by sequencing
shRNAs present in a FasR-positive population. Ultimately this
screen identified a mechanism by which the oncogene Ras
mediated epigenetic silencing of the Fas gene, thus allowing
tumour cells to avoid apoptosis, one of the hallmarks of a cancer
cell.
THE PROCESS
The commercial availability and relative ease of use of RNAi
libraries now means that most research labs are able to perform
an RNAi screen, be it genome wide or targeting a smaller gene
Figure 1 RNA interference. For simplicity we have shown how
microRNAs (miRNAs) can mediate RNA interference in mammalian cells
by causing the degradation of protein-coding transcripts. Non-protein
coding miRNAs are transcribed from the genome and then processed in
the nucleus into shorter RNA species bearing a hairpin structure
(shRNAs); these hairpin structures, consisting of a ‘‘stem’’ and a ‘‘loop’’,
are caused by base pairing between short regions of the RNA sequence
(these form the ‘‘stem’’) separated by a short sequence that does not
form base pairs (which forms the ‘‘loop’’). shRNAs are exported from the
nucleus and further processed into small RNA duplexes (siRNAs) formed
from the stem of the shRNA. siRNAs are loaded into the RNA-induced
silencing complex (RISC). This complex facilitates binding between one
of the siRNA strands and protein-coding mRNAs that have nucleotide
sequence complementary to the siRNA. Once siRNA/mRNA binding has
occurred, and thus the target mRNA transcript has been recognised, a
nuclease in RISC degrades the mRNA, thus ultimately reducing the
amount of mRNA that is available for translation and protein production.
This mechanism can be exploited experimentally to silence specific
genes. Synthetic siRNAs can be delivered into cells by transfection and
are readily loaded on to the RISC and mediate degradation of mRNAs
with significant sequence complementarity. Viruses or plasmids
containing miRNA-coding or shRNA-coding sequences can also be
introduced into mammalian cells and these mimic the production of
endogenous miRNA and shRNA and are processed into siRNA as before.
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should be considered before embarking upon such an enterprise.
As with any well thought out experiment, the screen assay to be
measured must carefully reflect the clinical, pharmacological or
biological question. The assay system must also be robust,
reproducible and affordable. Most laboratories use human
tumour cell lines for RNAi screens, as these can be routinely
grown and transfected but, depending on the phenotype
examined, the use of a non-human model system might be
considered. The biggest advantage is cost, which can be
significantly lower in model organisms because of the ability
of C elegans and Drosophila melanogaster to take up long dsRNAs
by feeding or soaking methods, eliminating the requirement for
expensive transfection reagents. Recent studies indicate that
many results from RNAi screens in model organisms translate
to humans.
11 Of equal importance is the choice of RNAi library.
Given the many different formats of RNAi libraries available,
this decision is governed by the choice of a pooling or non-
pooled approach. If a pooling strategy is chosen, screens have
been mostly limited to the vector-based libraries. Whether the
assay system requires long-term or short-term gene silencing
also needs to be taken into account. Stable integration of vector
backbones combined with antibiotic selection cassettes make
vector libraries advantageous if long-term silencing is a
necessity. However, non-vector siRNA libraries should not be
discounted, as transfection efficiencies are normally higher
using these smaller nucleic acids, and significant gene silencing
can often still be observed after 7 days. Finally, there is the
question of reagent lifespan. Vector-based libraries are poten-
tially renewable, but this can be time consuming and expensive.
Many prefer the option of having a ‘‘ready-to-go’’ reagent,
acknowledging that silencing technology is still improving.
Finally, as with any experiment, positive and negative controls
should ideally be used in RNAi screens. These controls allow the
dynamic range of the assay to be estimated and also, if
replicated several times within a library, serve as a form of data
quality control. Ideally a negative control would take the form
of an RNAi reagent that engages the gene-silencing apparatus
but silences a gene that has no effect on the phenotype of
interest, such as a synthetic gene in the target cell line such as
GFP, the silencing of which can be readily monitored. For
example, using cell lines that express a fluorescent protein, such
as GFP, in combination with an siRNA that targets GFP, would
provide an ideal negative control for many screens. However,
the use of such a system may restrict the user to a limited
number of cell lines, and the norm is to use non-targeting
siRNA.
12 Although some commercial non-targeting controls are
well suited to this purpose, some induce off-target effects (see
below) that lead to cell death, and the user is well advised to
assess the effect of each control on the phenotype in question,
comparing with mock-transfected cells.
Positive controls can be used to define the magnitude of
change that is thought to constitute a meaningful biological
effect and verify that the screen is returning valid biological
data. They also provide biologically relevant thresholds for
identifying positive hits from a screen. Comparison of positive
and negative controls also allows the screening window
coefficient or Z factor
13 to be estimated, which describes the
suitability of the assay system for large-scale screening.
Checking that the screen is suitably robust reduces statistical
false positives and negatives and saves time and money spent on
wasted screen data or attempting to validate false positives.
Once decisions have been made on the factors described
above, a typical screening strategy is as follows. Firstly,
experimental parameters need to be optimised. Probably, the
best place to start is to ensure that high-efficiency transfection
or infection can be achieved in the format (multi-well plate or
other) that is to be used for the screen. Ideally, one is looking for
transfection/infection conditions that enable efficient delivery
of the RNAi reagent without causing excessive, non-specific
toxicity. One simple trick for assessing RNAi delivery para-
meters is to transfect or infect cells with RNAi reagents that
silence genes that are essential for cell viability and compare cell
death with control transfected cells. In human tumour cells,
RNAi reagents targeting Polo-like kinase 1 are often used for this
purpose, as knocking down this kinase consistently kills most
cancer cells.
14 Different transfection reagents and procedures
should be tried here, but more often than not the best place to
Table 1 RNAi library formats
Library type Advantages Disadvantages
siRNA
c normally arrayed in 96-well or 384-
well plates
c can combine multiple siRNAs
targeting different sequences in the
same gene in one well
(SMARTPools)
c can be purchased in ‘‘ready-to-
transfect’’ aliquots or in larger
amounts that require replating
c can also be arrayed on slides
c Consistent quality of reagents
c Ease of use and readily transfectable
c Chemical modification of siRNA can
limit off-target effects
c Finite resource
c Target cells need to be transfectable
c Relatively short period of silencing
c Not suited to pooling strategies
shRNA as:
c plasmid DNA arrayed in 96-well or
384-well plates for transfection
c viral particles in multi-well plates
(one shRNA per well)
c pools of plasmids or viral particles
c Renewable resource
c Viral vectors enable silencing in
difficult-to-transfect cells
c Suited to pooled screens as well as
arrayed screens
c Stable integration of silencing
machinery into host cell genome
enables longer-term silencing
c Varying vector formats available that
allow inducible silencing, tracking of
silencing machinery, etc
c Reduced ease of use: require
preparation of plasmid DNA and, in the
case of viral-based libraries, viral
packaging
c Viral use often requires biological
containment
c Pooled screens require significant
deconvolution
Supplier websites: www.openbiosystems.com; www.dharmacon.com; www.origene.com; www.scbt.com; www.ambion.com;
www.sigmaaldrich.com; www.systembio.com.
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lines found on RNAi reagent suppliers’ websites. Once efficient
RNAi delivery can be achieved, positive and negative RNAi
reagents should be used to assess whether the screen phenotype
can be robustly measured. The key issues here are scale of effect,
variability and reproducibility; if the screen assay is such that
the difference between positive and negative controls can only
be observed rarely, the omens for the screen itself are poor.
Having addressed these concerns, one may consider a pilot
screen. This is especially important if one is to embark upon a
genome-wide screen, and normally involves testing control
RNAi reagents alongside a panel of a few hundred selected
RNAi reagents. Again this pilot will assess the reproducibility of
the positive and negative controls and decipher the hit rate of
the screen. If the hit rate is very high, it may suggest lack of
specificity of the screen. Pilot screens may also identify
problems such as time and space limitations. It is also worth
noting here the main reason why screens fail; the inability to
precisely reproduce experimental conditions from the initial
determination of screen conditions through to the screen itself.
Given that most screen conditions are determined empirically
(ie, by titrating variables such as cell number, amount of siRNA,
etc), it is perhaps wise to standardise all procedures, by using
identical batches of cells, media, etc as well as carefully timing
and reproducing all of the steps involved in the screen process.
It is also absolutely vital to consider the analysis of screen
data before embarking upon the screen itself. Perhaps one of the
best methods of screen analysis has been described by Boutros et
al.
15 Their CellHTS software package uses a modification of the
Z score/median absolute deviation method of defining screen
hits. Although we will not go into this form of analysis in detail,
it is key that one understands the method of statistical analysis
before embarking on a screen, as this will inform how the screen
is performed and also allow an assessment of the quality of the
screen itself.
Once the screen and data analysis are performed, it is often
common to perform a secondary screen using only the control
RNAi reagents and those silencing the ‘‘hits’’ identified in the
Figure 2 RNAi screening formats. Top
panel: One gene per well screens target
each gene separately in a multi-well
format. Short-interfering RNAs (siRNAs),
short-hairpin RNA (shRNA) plasmids or
virally packaged shRNA constructs can
be used to transfect or infect cells.
Various readouts may be used to
determine the effect of RNAi on the
phenotype of interest; the measurement
of cell viability is common, and
luminescence-based plate readers are
often used for this purpose. Alternatively,
high-throughput microscopes may be
used to measure cellular phenotypes in
screens. Lower panel: In pooled screens,
pools of shRNA-expressing vectors are
introduced into cells by transfection or
infection. Cells are then exposed to a
selective agent such as a drug. In this
case, shRNAs that cause drug resistance
can be identified and quantified by
amplifying shRNA sequences from
genomic DNA in surviving cells.
Microarray analysis is ideal for detecting
shRNA sequences, as is Next Generation
Sequencing. For more details, see the
main text.
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eliminate the possibility of off-target effects, ie, effects that are
due to silencing of genes other than the intended targets.
Although silencing of genes via RNAi requires high comple-
mentarity to the target mRNA, off-target effects may require
considerably less, in a similar fashion to the microRNA
machinery. A 7–8-nucleotide ‘‘seed’’ region at the 59 end of
the anti-sense strand is most critical in generating off-target
effects, particularly when this seed region occurs in the 39
untranslated region of a potential off-target gene.
16 At present it
is not possible to completely eliminate off-target effects by
reagent design alone, although some of the commercial suppliers
now sell siRNAs that are chemically modified to limit such
effects. However, although some of these chemical modifica-
tions are able to reduce off-target effects, they may compromise
silencing efficiency. Ultimately, to demonstrate that knock-
down of the targeted gene is directly responsible for the
phenotype, it is important to perform ‘‘rescue or redundancy’’
experiments.
17 Rescue may involve reversing the phenotype
induced by the siRNA by re-expressing an siRNA-resistant
cDNA (one that has mismatches with the siRNA and cannot be
targeted for degradation). With the large number of hits that
result from RNAi screens, this is often not possible, and, in
many cases, overexpression of a cDNA has aberrant effects that
make this approach difficult to implement. In most cases,
redundancy is sufficient to confirm specificity. This involves
demonstrating that multiple RNAi reagents targeting different
regions of the same target mRNA cause the same phenotype.
Silencing caused by individual RNAi reagents should also be
confirmed by quantitative real-time PCR or western blotting
the target protein. As alternative approaches, small-molecule
inhibitors of the ‘‘hit’’ proteins may be used to show that loss of
function can elicit the particular phenotype, as can the use of
‘‘dominant-negative’’ cDNA expression constructs or inhibiting
antibodies.
Validating individual hits from a screen can often be a more
time-consuming and expensive enterprise than the screen itself.
Given this, one may choose to use a more rapid approach that
exploits the improvements in bioinformatic analysis that are
now available. For example, one can now take the list of ‘‘hit’’
genes from a RNAi screen and subject this list to some form of
pathway analysis; where a number of hits from the screen fall
into the same biological pathway, or indeed have a well-
established physical or function interaction, one has some
confidence that the effects are real. To achieve this, one has the
option of using many of the pathway analysis tools that are
publicly available or even the commercial tools such as
Ingenuity (www.ingenuity.com). However, it must be noted
that this approach is only as good as the quality of the data in
the pathway or interaction database that is used. Furthermore,
this approach to validation is perhaps only appropriate for
whole-genome RNAi screens, as particular gene subset screens
may already be biased towards particular pathways.
APPLICATIONS FOR THE PATHOLOGIST
As the reader will see below, RNAi screens represent more of a
research tool rather than an application that could be used in
the diagnostic laboratory. Nevertheless, individual RNAi
reagents, rather than RNAi libraries and screens, do serve one
obvious application for use in the diagnostic laboratory. The
ability of RNAi reagents to knockdown the expression of
specific proteins makes them ideal for the validation of
antibodies that are to be used in diagnostic tests. For example,
cells transfected with siRNAs targeting one gene/protein, when
compared with control-transfected cells, serve as ideal controls
for identifying the optimal conditions for the use of an
antibody.
Where RNAi screens are involved, the interest to the
pathologist is their utility in the dissection of basic cellular
pathways, but also in more translational areas such as
identifying novel therapeutic approaches and mechanisms of
drug resistance. To illustrate this, we present a number of ‘‘case
reports’’ describing a selection of the more pertinent RNAi
screens.
Case history 1: viral infection
Flaviviruses, such as West Nile virus, represent a significant risk
to human health. To understand what determines whether a
cell can be infected with West Nile virus, Krishnan and
Glossary
c RNAi, RNA interference. The process by which RNAs that
encode proteins (messenger RNAs (mRNAs)) are degraded in
a sequence-specific manner by binding to a short interferring
RNA.
c siRNA, short interfering RNA. The RNA species that binds
mRNA in the RNA-induced silencing complex (RISC). The
mRNA/siRNA interaction activates the nuclease activity of
RISC, leading to degradation of the mRNA.
c shRNA, short hairpin RNA. A siRNA precursor, encompassing
a ‘‘stem’’ and a ‘‘loop’’ structure formed by base pairing
between short regions of the RNA sequence (these form the
‘‘stem’’) separated by a short sequence that does not form
base pairs (which forms the ‘‘loop’’).
c microRNA (miRNA), a non-protein-coding RNA species. One of
the known functions of miRNAs in mammalian cells is in RNA
interference
c pooled/non-pooled screens. In non-pooled screens, RNAi
reagents targeting one gene are introduced into a single-cell
population. Non-pooled screens are normally carried out in
multi-well plates, with each well representing RNAi reagents
targeting one gene. In pooled screens, RNAi reagents targeting
a number of genes are introduced into the cell population at
the same time.
c Infection, the process by which DNA, packed within a viral
coat, is introduced into cells. DNA-encoding miRNAs or
shRNAs can be packaged as virus and infected into cells.
c Transfection, the process by which ‘‘naked’’ or non-virally
packaged DNA is introduced into cells. Normally this is
achieved by binding DNA to a lipid; the resultant lipid sphere
binds to and merges with the target cell’s plasma membrane,
releasing the DNA into cells.
Take-home messages
c RNAi screens are now becoming part of everyday technology
used in the research laboratory.
c There are a number of ways to use this technology based on
the type of question asked and the scale of the undertaking.
c RNAi technology has the potential to dissect basic biological
phenotypes, as well as providing insight into clinically relevant
questions.
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18 performed a genome-wide RNAi screen to identify
human genes that control viral internalisation. Using a siRNA
library arrayed in 96-well plates, 21 121 human genes were
silenced in an immortal cell line and the ability of virus to infect
cells was measured by immunostaining cells for expression of a
viral envelope protein followed by high-throughput microscopic
imaging. This analysis identified 305 host cell proteins that
affect West Nile virus infection, including the ubiquitin ligase
CBLL1. Bioinformatic analysis of the ‘‘hits’’ identified in the
screen also identified a role for proteins involved in endoplasmic
reticulum-associated degradation and cell adhesion, not only
furthering our basic understanding of how host cells determine
viral infection, but also suggesting novel therapeutic
approaches.
Case history 2: myelodysplastic syndrome
5q-syndrome, a subtype of myelodysplastic syndrome, is
characterised by a defect in erythroid differentiation and, as
the name suggests, is thought to be caused by haploinsuffi-
ciency of one gene or a number of genes located within a
1.5-megabase region of chromosome 5q. To identify the
causative defects in this syndrome, Ebert and colleagues
19 used
lentivirally expressed shRNAs to target all 40 genes in the
1.5-megabase common deleted region on 5q. This RNAi screen
identified that loss of function of the ribosomal subunit protein
RPS14 causes a similar phenotype to 5q-syndrome in otherwise
normal haematopoietic progenitor cells. Exogenous expression
of RPS14 rescued the disease phenotype in patient-derived bone
marrow cells.
Case history 3: drug resistance
Many RNAi screens have been carried out with the aim of
exploring the mechanism of resistance to chemotherapeutic
drugs. For example, we recently used an RNAi screen to identify
novel determinants of response to the commonly used breast
cancer therapy, tamoxifen.
20 Breast tumour cells were trans-
fected with siRNA and then divided into tamoxifen-treated and
control groups. Those siRNAs that modified the expected
response to tamoxifen were investigated further. This screen
showed that silencing of the kinase CDK10 caused resistance to
tamoxifen and also other endocrine treatments such as
Faslodex. Further investigation showed that CDK10 suppres-
sion leads to upregulation of cell signalling pathways that
abrogate the effects of tamoxifen, thus causing drug resistance.
Notably, patients with breast cancer whose tumours expressed
low concentrations of CDK10 were shown to relapse much
earlier than those with high CDK10 expression, suggesting that
CDK10 may serve as a biomarker. Before this RNAi screen, there
was no indication that CDK10 expression could determine
response to endocrine treatments, illustrating the benefit of
such approaches. Using a similar RNAi screen, Swanton and
colleagues
21 showed that the ceramide-transport protein,
COL4A3BP, determined resistance to a number of cytotoxic
agents. COL4A3BP expression was also shown to be raised in
drug-resistant cell lines and in paclitaxel-resistant ovarian
tumours, suggesting that COL4A3BP expression is a cause of
drug resistance and a potential target for use in chemotherapy-
resistant cancers.
21 Bernards and colleagues
22 used a large-scale
RNAi screen to discover determinants of trastuzumab
(Herceptin) resistance in breast cancer. This screen identified
the phosphatidylinositol 3-kinase (PI3K) pathway as modulat-
ing sensitivity to the drug, with mutations in a pathway
member, PIK3CA, conferring resistance to trastuzumab.
Significantly, this RNAi screen suggests that analysis of the
PI3K pathway may provide biomarkers to predict the likelihood
of patient response to trastuzumab treatment.
SUMMARY
Although RNAi technology is still evolving, it is also now
suitably mature that RNAi screens are now becoming part of
the everyday armoury of the research laboratory. Hopefully, we
have shown you that there are a number of different ways to
use this technology, primarily based on the type of question one
has and the scale of the undertaking that one wishes to perform.
Nevertheless, it is certainly becoming clear that this technology
has the potential to allow the pathologist to not only dissect
basic biological issues but also questions of a more translational
bent.
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